Septic shock

References

• Gaffin SL, Lachman E. The use of antilipopolysac- charide [anti-LPS] antibodies in the management of septic shock: a preliminary report. S Afr Med J 1984: 65(5): 158–61
   PubMed Web of Science ®Google Scholar
• The Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 1987: 317(11): 659–65
   PubMed Web of Science ®Google Scholar
• Wolff SM, Bennett JV. Gram-negative-rod bacteremia. (Editorial) N Engl J Med 1974: 291 (14): 733–4
   PubMed Web of Science ®Google Scholar
• Luce JM. Pathogenesis and management of septic shock. Chest 1987: 91(6): 883–8
   PubMed Web of Science ®Google Scholar
• Parker MM, Shelhamer JH, Natanson C, et al. Serial cardiovascular variables in survivors and nonsurvivors of human septic shock: heart rate as an early predictor of prognosis. Crit Care Med 1987: 15(10): 923–9
   PubMed Web of Science ®Google Scholar
• Groeneveld AB, Bronsveld W, Thijs LG. Hemodynamic determinants of mortality in human septic shock. Surgery 1986: 99(2): 140–53
   PubMed Web of Science ®Google Scholar
• Zimmerman J J, Dietrich KA. Current perspectives on septic shock Pediatr Clin North Am 1987: 34(1): 131–63
   PubMed Web of Science ®Google Scholar
• Mizock B. Septic shock: a metabolic perspective. Arch Intern Med 1984: 144(3): 579–85
   PubMedGoogle Scholar
• Civetta JM, Taylor RW, Kirby RR, eds. Critical care. Philadelphia: JB Lippincott, 1988: 903–4
   Google Scholar
• Cerra FB. Metabolic monitoring: the key to the microcirculation and cellular metabolism. In: Shoemaker WC. Thompson WL, eds. Critical care: the state of the art. Fullerton. CA: Society of Critical Care Medicine. 1982: 1–21
   Google Scholar
• Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986: 315(9): 552–8
   PubMed Web of Science ®Google Scholar
• The EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 1987: 317(27): 1692–8
   PubMed Web of Science ®Google Scholar
• Eisenberg PR, Jaffe AS, Schuster DP. Clinical evaluation compared to pulmonary artery catheterization in the hemodynamic assessment of critically ill patients. Crit Care Med 1984: 12(7): 549–53
   PubMed Web of Science ®Google Scholar
• Cerra FB, Border JR. McMenamy RH, et al. Multiple systems organ failure. In: Cowley RA. Trump BF. eds. Pathophysiology of shock, anoxia, and ischemia. Baltimore: Williams & Wilkins. 1982: 254–70
   Google Scholar
• O'Donnel TF, Clowes GH Jr, Blackburn GL, et al. Proteolysis associated with a deficit of peripheral energy fuel substrates in septic man. Surgery 1976: 80(2): 192–200
   PubMed Web of Science ®Google Scholar
• Houtchens BA, Westenskow DR. Oxygen consumption in septic shock: collective review. Circ Shock 1984: 13(4): 361–84
   PubMedGoogle Scholar
• Filkins JP. Monokines and the metabolic pathophysiology of septic shock. Fed Proc 1985: 44(2): 300–4
   PubMedGoogle Scholar
• Blackburn GL. Lipid metabolism in infection. Am J Clin Nutr 1977: 30(8): 1321–32
   PubMed Web of Science ®Google Scholar
• Cerra FB, Siegel JH, Coleman B, et al. Septic autocannibalism: a failure of exogenous nutritional support. Ann Surg 1980: 192(4): 570–80
   PubMed Web of Science ®Google Scholar
• Freund HR, Ryan JA Jr, Fischer JE. Amino acid derangements in patients with sepsis: treatment with branched chain amino acid rich infusions. Ann Surg 1978: 188(3): 423–30
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Mier JW. Lymphokines. N Engl J Med 1987: 317(15): 940–5
   PubMed Web of Science ®Google Scholar
• Beutler B, Mahoney J, Le Trang N, et al. Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J Exp Med 1985: 161 (5): 984–95
   PubMed Web of Science ®Google Scholar
• Beutler BA, Milsark IW, Cerami A. Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J Immunol 1985: 135(6): 3972–7
   PubMed Web of Science ®Google Scholar
• Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986: 163(3): 740–5
   PubMed Web of Science ®Google Scholar
• Sato N, Goto T, Haranaka K, et al. Actions of tumor necrosis factor on cultured vascular endothelial cells: morphologic modulation, growth inhibition, and cytotoxicity. J Natl Cancer Inst 1986: 76(6): 1113–21
   PubMedGoogle Scholar
• Dinarello CA, Cannon JG, Wolff SM, et al. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 1986: 163(6): 1433–50
   PubMed Web of Science ®Google Scholar
• Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectln. Science 1986: 234(4775): 470–4
   PubMed Web of Science ®Google Scholar
• Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectln/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985: 229(4716): 869–71
   PubMed Web of Science ®Google Scholar
• Tracey KJ, Fong Y, Hesse DG, et al. Anticachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987: 330(6149): 662–4
   PubMed Web of Science ®Google Scholar
• Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987: 1 (8529): 355–7
   PubMed Web of Science ®Google Scholar
• Girardin E, Gran GE. Dayer JM, et al. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med 1988: 319(7): 397–400
   PubMed Web of Science ®Google Scholar
• Michie HR, Manogue KR, Spriggs DR, et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988: 318(23): 1481–6
   PubMed Web of Science ®Google Scholar
• Beutler B, Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med 1987: 316(7): 379–85
   PubMed Web of Science ®Google Scholar
• Beutler B, Krochln N, Milsark IW. et al. Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science 1986: 232(4753): 977–80
   PubMed Web of Science ®Google Scholar
• Bone RC, Fisher CJ Jr, Clemmer TP, et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987: 317(11): 653–8
   PubMed Web of Science ®Google Scholar